{"doi":"10.1002/mrm.29896","title":"Nuclear Overhauser enhancement imaging at −1.6 ppm in rat brain at 4.7T","abstract":"PURPOSE: A new nuclear Overhauser enhancement (NOE)-mediated saturation transfer signal at around -1.6 ppm, termed NOE(-1.6), has been reported at high fields of 7T and 9.4T previously. This study aims to validate the presence of this signal at a relatively low field of 4.7T and evaluate its variations in different brain regions and tumors. METHODS: Rats were injected with monocrystalline iron oxide nanoparticles to reduce the NOE(-1.6) signal. CEST signals were measured using different saturation powers before and after injection to assess the presence of this signal. Multiple-pool Lorentzian fits, with/without inclusion of the NOE(-1.6) pool, were performed on CEST Z-spectra obtained from healthy rat brains and rats with 9L tumors. These fits aimed to further validate the presence of the NOE(-1.6) signal and quantify its amplitude. RESULTS: The NOE(-1.6) signal exhibited a dramatic change following the injection of monocrystalline iron oxide nanoparticles, confirming its presence at 4.7T. The NOE(-1.6) signal reached its peak at a saturation power of ∼0.75 μT, indicating an optimized power level. The multiple-pool Lorentzian fit without the NOE(-1.6) pool showed higher residuals around -1.6 ppm compared to the fit with this pool, further supporting the presence of this signal. The NOE(-1.6) signal did not exhibit significant variation in the corpus callosum and caudate putamen regions, but it showed a significant decrease in tumors, which aligns with previous findings at 9.4T. CONCLUSION: This study successfully demonstrated the presence of the NOE(-1.6) signal at 4.7T, which provides valuable insights into its potential applications at lower field strengths.","journal":"Magnetic Resonance in Medicine","year":2023,"id":364729,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9527,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1091645,"name":"Yashwant Kurmi","orcid":"0000-0003-4986-2106","position":1,"is_corresponding":false},{"id":344640,"name":"Zhongliang Zu","orcid":"0000-0001-7361-7480","position":2,"is_corresponding":false},{"id":1081756,"name":"Malvika Viswanathan","orcid":"0009-0001-9522-0780","position":0,"is_corresponding":true}],"reference_count":63,"raw_metadata":null,"created_at":"2026-07-19T01:14:41.218128Z","pmid":"37867419","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}